CDK4 and neoplasm: Finally, CDK4/6 inhibition can re‐sensitize tumours to immune checkpoint blockade (Xue et al, 2007; Krizhanovsky et al, 2008; Kang et al, 2011; Acosta et al, 2013; Goel et al, 2017; Chaikovsky & Sage, 2018; Deng et al, 2018; Jerby‐Arnon et al, 2018; Ruscetti et al, 2018, 2020).